Trade Aquestive Therapeutics, Inc. - AQST CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0330 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023485% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001262% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.8685 |
| Open | 2.8185 |
| 1-Year Change | -34.07% |
| Day's Range | 2.8185 - 3.0285 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 31, 2025 | 2.8685 | 0.0100 | 0.35% | 2.8585 | 2.9385 | 2.7985 |
| Mar 28, 2025 | 2.9985 | -0.1100 | -3.54% | 3.1085 | 3.1785 | 2.9585 |
| Mar 27, 2025 | 3.1885 | 0.1500 | 4.94% | 3.0385 | 3.2185 | 3.0385 |
| Mar 26, 2025 | 3.1085 | -0.0400 | -1.27% | 3.1485 | 3.1685 | 3.0385 |
| Mar 25, 2025 | 3.2085 | -0.0400 | -1.23% | 3.2485 | 3.2785 | 3.1585 |
| Mar 24, 2025 | 3.2285 | 0.0100 | 0.31% | 3.2185 | 3.2985 | 3.1985 |
| Mar 21, 2025 | 3.2085 | 0.2400 | 8.08% | 2.9685 | 3.2285 | 2.9685 |
| Mar 20, 2025 | 3.0985 | 0.2500 | 8.78% | 2.8485 | 3.1785 | 2.8485 |
| Mar 19, 2025 | 2.9685 | 0.2600 | 9.60% | 2.7085 | 2.9685 | 2.7085 |
| Mar 18, 2025 | 2.7385 | -0.0400 | -1.44% | 2.7785 | 2.8485 | 2.6985 |
| Mar 17, 2025 | 2.8385 | 0.0600 | 2.16% | 2.7785 | 2.8985 | 2.7785 |
| Mar 14, 2025 | 2.8285 | 0.0600 | 2.17% | 2.7685 | 2.8785 | 2.7585 |
| Mar 13, 2025 | 2.7085 | -0.1900 | -6.56% | 2.8985 | 3.0385 | 2.6985 |
| Mar 12, 2025 | 2.9285 | 0.3000 | 11.41% | 2.6285 | 2.9485 | 2.6085 |
| Mar 11, 2025 | 2.6385 | 0.1300 | 5.18% | 2.5085 | 2.6485 | 2.4785 |
| Mar 10, 2025 | 2.5285 | -0.0600 | -2.32% | 2.5885 | 2.6485 | 2.4885 |
| Mar 7, 2025 | 2.6385 | 0.1000 | 3.94% | 2.5385 | 2.6785 | 2.4585 |
| Mar 6, 2025 | 2.5585 | 0.1400 | 5.79% | 2.4185 | 2.7285 | 2.4185 |
| Mar 5, 2025 | 2.7885 | 0.0700 | 2.57% | 2.7185 | 2.8285 | 2.7185 |
| Mar 4, 2025 | 2.7185 | 0.1800 | 7.09% | 2.5385 | 2.7285 | 2.5285 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Aquestive Therapeutics, Inc. Company profile
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing differentiated products which leverage PharmFilm. Its late-stage product pipeline focused on the treatment of central nervous system (CNS), diseases and an earlier stage pipeline including treatment of anaphylaxis. Its commercialized licensed product is Suboxone, a sublingual film formulation of buprenorphine and naloxone, for the treatment of opioid dependence. Its CNS portfolio focused on epilepsy includes, Sympazan an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut syndrome (LGS). Its portfolio also includes Suboxone a sublingual film formulation of buprenorphine and naloxone, respectively an opioid agonist and antagonist for the treatment of opioid dependence.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Aquestive Therapeutics Inc revenues increased 11% to $50.8M. Net loss increased 26% to $70.5M. Revenues reflect Ex-United States segment increase of 63% to $8M, United States segment increase of 5% to $42.9M. Higher net loss reflects Interest expense related to the sale increase from $2M to $12.4M (expense), Stock-based Compensation in R&D increase of 21% to $881K (expense).
Equity composition
Common Stock $.01 Par, Shares auth. and o/s after the offering: 100M auth., 15,029,412 issd. Insiders own approx. 1% (after the IPO). IPO: TBA. 4M shares Offered. 03/08, IPO withdrawn.
| Industry: | Pharmaceuticals (NEC) |
30 Technology Dr
WARREN
NEW JERSEY 07059-5166
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com